Standardized assessment of the HER2 status in breast cancer by immunohistochemistry

Laboratory Medicine

Volumn 42, Issue 8, 2011, Pages 459-467

  Hicks, David G ^a   Schiffhauer, Linda ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Breast cancer; HER2; Immunohistochemistry; Standardization; Test interpretation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FORMALDEHYDE; TRASTUZUMAB;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER PATIENT; CANCER SURGERY; CLINICAL PRACTICE; ENZYME ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATION; NEEDLE BIOPSY; PRACTICE GUIDELINE; PROTEIN ANALYSIS;

EID: 79961145364     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMGZZ58CTS0DBGTW     Document Type: Article

References (20)

1. Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: The importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med. 2008;132:1008-1015.
2. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502.
3. Hicks DG, Kulkarni S. HER2+ breast cancer: Review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008;129:263-273.
4. Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008;16:513-520.
5. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
6. Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320-368.
7. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004;319:1-11.
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
9. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: Panel summary and guidelines. Arch Pathol Lab Med. 2009;133:611-612.
10. Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005;29:1221-1227.
11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
12. Sherman ME, Howatt W, Blows FM, et al. Molecular pathology in epidemiologic studies: A primer on key considerations. Cancer Epidemiol Biomarkers Prev. 2010;19:966-972.
13. Hewitt SM, Lewis FA, Cao Y, et al. Tissue handling and specimen preparation in surgical pathology: Issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2008;132:1929-1935.
14. Khoury T, Sait S, Hwang H, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22:1457-1467.
15. Kulkarni S, Hicks DG. HER2-positive early breast cancer and trastuzumab: A surgeon's perspective. Ann Surg Oncol. 2008;15:1677-1688.
16. Goldstein NS, Hewitt SM, Taylor CR, et al. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007;15:124-133.
17. Goldstein NS. Standardized predictive receptor immunohistochemical assays: The view forward from our past. Am J Clin Pathol. 2010;133:681-683.
18. Arnedos M, Nerurkar A, Osin P, et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 2009;20:1948-1952.
19. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: A technical review with interpretive guidelines. Hum Pathol. 2005;36:250-261.
20. Crowe JP, Patrick RJ, Rybicki LA, et al. A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. Breast. 2006;15:728-735.